The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up-Reference-Cited by-同舟云学术

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Published:2021-06-08 Issue:5 Volume:185 Page:935-944
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Lebwohl M.¹,Deodhar A.²,Griffiths C.E.M.³^ORCID,Menter M.A.⁴,Poddubnyy D.⁵,Bao W.⁶,Jehl V.⁷,Marfo K.⁷,Primatesta P.⁷,Shete A.⁷,Trivedi V.⁶,Mease P.J.⁸

Affiliation:

1. Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai New York City NY USA

2. Oregon Health & Science University Portland OR USA

3. The Dermatology Centre The University of Manchester Manchester Academic Health Science Centre Salford Royal NHS Foundation Trust Manchester UK

4. Division of Dermatology Baylor Scott & White Health Dallas TX USA

5. Division of Gastroenterology Infectious Diseases and Rheumatology, Charité, Universitätsmedizin Berlin, Germany, and Epidemiology Unit German Rheumatism Research Centre Berlin Germany

6. Novartis Pharmaceuticals Corporation East Hanover NJ USA

7. Novartis Pharma AG Basel Switzerland

8. Department of Rheumatology Swedish Health Services/Providence St Joseph Health and University of Washington Seattle WA USA

Funder

Novartis

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20136

Reference50 articles.